Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.77 |
| ▸ | RAB9A | P51151 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115263 | 1.00 | NPC1 (0.77) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL3122021 | 1.00 | NPC1 (0.77) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL3115258 | 1.00 | NPC1 (0.77) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL19564562 | 0.91 | NPC1 (0.65) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL22282966 | 0.89 | NPC1 (0.62) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL14441230 | 0.82 | RAB9A (0.91) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL20855413 | 0.82 | NPC1 (0.67) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL3123638 | 0.82 | GPR183 (0.72) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL3123635 | 0.82 | GPR183 (0.72) | NPC1RAB9AKMT2AMEN1GAA | |
| SCHEMBL4094287 | 0.82 | HRH3 (0.69) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | claimed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | claimed |
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | PRPH, BDNF, GAP43 | NPC1 725/4885RAB9A 803/4885KMT2A 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.